Many types of cancers and the side effects of treatment (e.g., radiation, chemotherapy, surgery) manifest in various forms of acute and chronic nociceptive and neuropathic pain. We have developed an optimized specific molecule ratios (MP-10X) for synergism that mitigates the side effects often inherent in the treatment of pain.
MP-10X line of formulations targets pain types through the activation of specific molecular mechanisms. Currently, we are in an early clinical application targeting pilot clinical studies with cancer patients. These formulations are delivered sublingually/transmucosally to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit.
Our molecules of interest include natural cannabinoids and new chemical molecules that target endocannabinoid system, thereby exhibiting demonstrable effects against various types of nociceptive and neuropathic pain, with negligible toxicity. They can selectively regulate several receptors- and transporter-mediated biological functions inherent in the perception of pain* and many of them with analgesic qualities do not have the psychotropic.
*Modulation of CB1 and CB2 receptors and transient receptor potential cation channel (TRPV1, TRPV2, TRPA1, TRPM8) activation are well-described targets of analgesia by drug molecules in many types of pain. Furthermore, some molecules have the potential to regulate pain through interactions with α3 glycine receptors, G-coupled protein receptor GPR-55, serotonin receptors, adenosine A1 receptors, α2 adrenoceptors, and eCB (anandamide) reuptake.